0000899243-22-039460.txt : 20221228 0000899243-22-039460.hdr.sgml : 20221228 20221228183033 ACCESSION NUMBER: 0000899243-22-039460 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221227 FILED AS OF DATE: 20221228 DATE AS OF CHANGE: 20221228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Young Jonathan CENTRAL INDEX KEY: 0001779805 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 221495999 MAIL ADDRESS: STREET 1: C/O AKERO THERAPEUTICS, INC. STREET 2: 170 HARBOR WAY 3RD FL CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-12-27 0 0001744659 Akero Therapeutics, Inc. AKRO 0001779805 Young Jonathan C/O AKERO THERAPEUTICS, INC. 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Operating Officer Common Stock 2022-12-27 4 M 0 722 0.615 A 183171 D Common Stock 2022-12-27 4 M 0 11778 6.36 A 194949 D Common Stock 2022-12-27 4 S 0 12500 49.5687 D 182449 D Common Stock 20000 I By EA Irrevocable Trust Common Stock 20000 I By CM Irrevocable Trust Common Stock 20000 I By JL Irrevocable Trust Employee Stock Option (Right to Buy) 6.36 2022-12-27 4 M 0 11778 0.00 D 2029-01-15 Common Stock 11778 48478 D Employee Stock Option (Right to Buy) 0.615 2022-12-27 4 M 0 722 0.00 D 2028-10-17 Common Stock 722 92098 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 9, 2021, previously adopted by the reporting person. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.50 to $49.75, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. This option shall vest and become exercisable in 48 equal monthly installments, commencing on January 1, 2019. The options are vested and currently exercisable. /s/ Jonathan Young 2022-12-28